Cargando…
Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists
Ulcerative colitis can cause debilitating symptoms and complications such as colonic strictures, colonic dysplasia, colorectal cancer, and toxic megacolon or perforation. Goals of treatment in ulcerative colitis include resolution of gastrointestinal symptoms, healing of colonic mucosa, and preventi...
Autores principales: | Fausel, Rebecca, Afzali, Anita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293927/ https://www.ncbi.nlm.nih.gov/pubmed/25609972 http://dx.doi.org/10.2147/TCRM.S55506 |
Ejemplares similares
-
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020) -
The Comparative Safety and Effectiveness of TNF-alpha Antagonists
por: Solomon, Daniel H.
Publicado: (2007) -
Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
por: Chu, Xinqiao, et al.
Publicado: (2023) -
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
por: Lim, Heejin, et al.
Publicado: (2018) -
Contribution of NOTCH signaling pathway along with TNF-α in the intestinal inflammation of ulcerative colitis
por: Ghorbaninejad, Mahsa, et al.
Publicado: (2019)